Compare Gilead Sciences, Inc. (GILD) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Gilead Sciences, Inc. trades at $136.55 (market cap $163.51B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $240.57 (market cap $45.27B). The key difference: Gilead Sciences, Inc. is far larger — about 3.6× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| GILD | TTWO | |
|---|---|---|
Market Cap | $163.51B | $45.27B |
Sector | Health | Media |
52-Week High | $155.80 | $262.29 |
52-Week Low | $108.22 | $189.69 |
Enterprise Value | $178.05B | $46.23B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Take-Two Interactive (TTWO) trades at $242.40, up 2.27% with bullish technical signals and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.80 surpassing the $0.563 estimate. Recent news highlights Grand Theft Auto VI pre-orders beginning June 25, 2026, priced at $79.99, driving positive sentiment. Despite a negative net income margin of -4.48% in 2025, revenue grew to $5.63B, and the company maintains a solid cash position of $1.47B.
The outlook is optimistic due to GTA VI's upcoming launch, with analysts projecting a consensus price target of $302.50. Risks include high debt levels and profitability challenges, but institutional bullishness and technical strength suggest potential upside. Investors should monitor execution on game launches and margin improvement for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
